Version history

{
  "session_id": "sess_SDA-2026-04-28-microglial-priming-causal-nd_task_66f1207e_ctx",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "scidex.core.llm.complete",
  "action": "assess",
  "content": "Domain expert assessment for analysis SDA-2026-04-28-microglial-priming-causal-nd: Microglial Priming as Upstream Causal Node Across AD, PD, ALS, MS: Three-Arm Causal Inference\n\nThe practical path is staged. Stage 1 should lock the data inputs, covariates, and endpoints. Stage 2 should run the most direct validation: triangulate cell-type-specific MR, scVelo trajectory direction, and longitudinal CSF cytokine Granger causality with disease-specific sensitivity analyses. Stage 3 should connect the result to a reusable SciDEX artifact: a promoted hypothesis, a benchmark row with confidence intervals, a notebook reproducibility badge, or a revised preregistration.\n\nFeasibility is moderate because the question is specific enough to test, but the intervention point may be less direct than the named entity. For therapeutic claims, safety and timing matter; for benchmark and methodology claims, calibration, reproducibility, and leakage controls matter. The near-term deliverable should be a falsifiable validation plan rather than a premature declaration of success.\n\nConsensus is strongest around using this analysis to sharpen the world model. Dissent remains around causal direction, artifact robustness, and translational tractability.",
  "tokens_used": "311",
  "persona_id": "persona-domain_expert"
}